• 1
    Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH, Turek LP. Age sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 104: 33644.
  • 2
    Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 191: 46775.
  • 3
    Franco EL, Schlecht F, Saslow D. The epidemiology of cervical cancer. Cancer J 2003; 9: 34859.
  • 4
    Nonnenmacher B, Kruger Kjaer S, Svare EI, Scott JD, Hubbert NL, van den Brule AJ, Kirnbauer R, Walboomers JM, Lowy DR, Schiller JT. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int J Cancer 1996; 68: 7049.
  • 5
    Wang ZH, Kjelberg L, Abdalla H, Wiklund F, Eklund C, Knekt P, Lehtinen M, Kallings I, Lenner P, Hallmans G, Mahlck CG, Wadell G et al. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 2000; 181: 45662.
  • 6
    Sigstad E, Lie AK, Luostarinen T, Dillner J, Jellum E, Lehtinen M, Thoresen S, Abeler V. A prospective study of the relationship between prediagnostic human papillomavirus seropositivitiy and HPV DNA in subsequent cervical carcinomas. Br J Cancer 2002; 87: 17580.
  • 7
    Sun Y, Eluf-Neto J, Bosch FX, Munoz N, Booth M, Walboomers JM, Shah KV, Viscidi RP. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil. Cancer Epidemiol Biomarkers Prev 1994; 3: 3417.
  • 8
    Gissmann L. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am 1996; 23: 62539.
  • 9
    Jochmus-Kudierlka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE, Seedorf K, Gissmann L. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989; 81: 16981704.
  • 10
    Sun Y, Eluf-Neto J, Bosch FX, Munoz N, Walboomers JM, Meijer CJ, Shah KV, Clayman B, Viscidi RP. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma. Cancer Epidemiol Biomarkers Prev 1999; 8: 93540.
  • 11
    Anders H, Rosenbauer J, Matiaske B. Reprasentative verzehrstudie in der Bundesrepublik Deutschland inclu. West-Berlin. In: Schriftenreithe der AGEV. Band 8. 1990.
  • 12
    Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer Multicenter Study. J Natl Cancer Inst 2003; 95: 177283.
  • 13
    Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, Gissmann L, Pawlita M. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998; 36: 47580.
  • 14
    Schwartz SM, Daling DR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao R-J, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 162636.
  • 15
    Zumbach K, Hoffmann M, Kahn T, Bosch F, Gottschlich S, Gorogh T, Rubert H, Pawlita M. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer 2000; 85: 81518.
  • 16
    American Joint Committee on Cancer. AJCC cancer staging manual, 5th edn. Chicago, IL: Lippincott Williams and Wilkins, 1997.
  • 17
    Smith EM, Ritchie JR, Summersgill KF, Hoffman HT, Wang DH, Haugen TH, Turek LP. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 44955.
  • 18
    Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Turek LP. p53 Polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 3349.
  • 19
    Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 287584.
  • 20
    Chehab FF, Doherty M, Cai SP, Kan YW, Cooper S, Rubin EM. Detection of sickle cell anaemia and thalassaemias [letter]. Nature 1987; 329: 2934.
  • 21
    Ting Y, Manos MM. Detection and typing of genital human papillomaviruses. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols, a guide to methods and applications. Berkeley, CA: Academic Press, 1990. 35667.
  • 22
    Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Rush BB et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169: 23540.
  • 23
    de Roda Husman A-M, Walboomers JMM, van den Brule AJC, Meijer CJLM, Snijders PJF. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 105762.
  • 24
    Altschul SF, Madden TL, Schaeffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acid Res 1997; 25: 3389402.
  • 25
    Hamšíková E, Ludvíková V, Tachezy R, Kovařík J, Břoušková L, Vonka V. Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int J Cancer 1998; 77: 68994.
  • 26
    Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001; 253: 15362.
  • 27
    Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989. 8891.
  • 28
    Rosner B. Fundamentals of biostatistics. Boston, MA: PWS-Kent, 1990. 170175.
  • 29
    SAS System for Windows, Version 8.2. Cary, NC: SAS Institute, 2001.
  • 30
    Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E, Koskela P, Luostarinen T, Paavonen J, Pukkala E, Sigstad E, Thoresen S et al. Evaluation of antibody response to HPV early proteins in women in whom cervical cancer developed one to 20 years later. Am J Obstet Gynecol 2003; 188: 4955.
  • 31
    Rosales R, Lopez-Contreras M, Corest RR. Antibodies against human papillomavirus (HPV) type 16 an 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA. J Med Virol 2001; 65: 73644.
  • 32
    Mork J, Lie K, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Purkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck. N Engl J Med 2001; 344: 112531.
  • 33
    Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang DH, Klussmann JP, Turek LP, Haugen TH. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 33644.
  • 34
    Friesland S,. Mellin H, Munck-Wikland E, Nilsson A, Lindholm J, Dalianis T, Lewensohn R. Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma—relation to radiotherapy response and survival. Anticancer Res 2001; 21: 52934.
  • 35
    Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 2002; 62: 736471.
  • 36
    Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001; 125: 19.
  • 37
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Snyder DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 70920.
  • 38
    Carter JJ, Galloway DA. Humoral immune response to human papillomavirus infection. Clin Dermatol 1997; 15: 24959.